Peringatan Keamanan

Toxicity information regarding tezepelumab is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as opportunistic infections and other conditions related to immunosuppression. Symptomatic and supportive measures are recommended.L39504

Tezepelumab

DB15090

biotech approved investigational

Deskripsi

Asthma is a heterogeneous chronic obstructive respiratory disease with both "type 2" (T2) and T2-low endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling.A243764, A243769 Thymic stromal lymphopoietin (TSLP), an innate pleiotropic IL-2-family cytokine, has emerged as a key upstream regulator of chronic inflammation across asthma endotypes. Blocking the interaction of TSLP with the receptors TSLPR and IL-7R? improves asthma-associated biomarkers including eosinophil counts and IgE, FeNO, IL-5, and IL-13 levels.A243764, A243769, A243774 As existing asthma treatments such as omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab act on specific downstream mediators of the inflammatory response, they are mostly limited to treating T2 asthma.A243769 Conversely, tezepelumab, which targets the upstream master regulator TSLP, has the potential to be effective across asthma endotypes.A243764, A243769, A243774

Tezepelumab is a human monoclonal IgG2? antibody directed against TSLP produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.L39504 Tezepelumab was also approved by the European Commission on September 19, 2022.L44712

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Tezepelumab has an elimination half-life of ~26 days.[L39504]
Volume Distribusi Tezepelumab has a central V<sub>d</sub> of 3.9 L and a peripheral V<sub>d</sub> of 2.2 L (for a 70 kg individual).[L39504]
Klirens (Clearance) Tezepelumab has an estimated clearance of 0.17 L/d (for a 70 kg individual).[L39504]

Absorpsi

When administered subcutaneously, tezepelumab reaches Cmax in approximately 3-10 days with an estimated absolute bioavailability of 77%, regardless of injection site choice.L39504 Tezepelumab displays dose-proportional pharmacokinetics over a range of 2.1-420 mg (0.01-2 times the recommended dose) following a single subcutaneous dose. With a 4-week dosing schedule, tezepelumab achieves steady-state kinetics after 12 weeks with a 1.86-fold Ctrough accumulation ratio.L39504 There are no clinically meaningful changes expected for tezepelumab pharmacokinetics in patients across patient populations, including those with renal or hepatic impairment.L39504

Metabolisme

As a human monoclonal antibody, tezepelumab is expected to be degraded by various proteolytic enzymes throughout the body.L39504

Rute Eliminasi

As a human monoclonal antibody, tezepelumab is eliminated primarily through catabolism; there is no evidence of target-mediated clearance at the therapeutic dose.L39504

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Tezepelumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Tezepelumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Tezepelumab.
Estrone Estrone may increase the thrombogenic activities of Tezepelumab.
Estradiol Estradiol may increase the thrombogenic activities of Tezepelumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Tezepelumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Tezepelumab.
Mestranol Mestranol may increase the thrombogenic activities of Tezepelumab.
Estriol Estriol may increase the thrombogenic activities of Tezepelumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Tezepelumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Tezepelumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Tezepelumab.
Tibolone Tibolone may increase the thrombogenic activities of Tezepelumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Tezepelumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Tezepelumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Tezepelumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Tezepelumab.
Zeranol Zeranol may increase the thrombogenic activities of Tezepelumab.
Equol Equol may increase the thrombogenic activities of Tezepelumab.
Promestriene Promestriene may increase the thrombogenic activities of Tezepelumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Tezepelumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Tezepelumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Tezepelumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Tezepelumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Tezepelumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Tezepelumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Tezepelumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Tezepelumab.
Formononetin Formononetin may increase the thrombogenic activities of Tezepelumab.
Estetrol Estetrol may increase the thrombogenic activities of Tezepelumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tezepelumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tezepelumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tezepelumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Tezepelumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Tezepelumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tezepelumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tezepelumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Tezepelumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tezepelumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Tezepelumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Tezepelumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Tezepelumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tezepelumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tezepelumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Tezepelumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tezepelumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tezepelumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Tezepelumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tezepelumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Tezepelumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Tezepelumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Tezepelumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tezepelumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tezepelumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Tezepelumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Tezepelumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Tezepelumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Tezepelumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Tezepelumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Tezepelumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Tezepelumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Tezepelumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Tezepelumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Tezepelumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Tezepelumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Tezepelumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Tezepelumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Tezepelumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Tezepelumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Tezepelumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Tezepelumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Tezepelumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Tezepelumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Tezepelumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Tezepelumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Tezepelumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Tezepelumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Tezepelumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Tezepelumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Tezepelumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Tezepelumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Tezepelumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Tezepelumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Tezepelumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Tezepelumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Tezepelumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Tezepelumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tezepelumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Tezepelumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Tezepelumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Tezepelumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Tezepelumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Tezepelumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Tezepelumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Tezepelumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Tezepelumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tezepelumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Tezepelumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Tezepelumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Tezepelumab.

Target Protein

Thymic stromal lymphopoietin TSLP

Referensi & Sumber

Synthesis reference: Michael R Comeau, James F Smothers, Bo-Rin P Yoon, Christopher Mehlin, "Antigen binding proteins capable of binding thymic stromal lymphopoietin." U.S. Patent US9284372B2, issued March 15, 2016.
Artikel (PubMed)
  • PMID: 33922072
    Pelaia C, Pelaia G, Crimi C, Maglio A, Gallelli L, Terracciano R, Vatrella A: Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma. Int J Mol Sci. 2021 Apr 22;22(9). pii: ijms22094369. doi: 10.3390/ijms22094369.
  • PMID: 31549891
    Marone G, Spadaro G, Braile M, Poto R, Criscuolo G, Pahima H, Loffredo S, Levi-Schaffer F, Varricchi G: Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin Investig Drugs. 2019 Nov;28(11):931-940. doi: 10.1080/13543784.2019.1672657. Epub 2019 Oct 10.
  • PMID: 31974038
    Nakajima S, Kabata H, Kabashima K, Asano K: Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses. Allergol Int. 2020 Apr;69(2):197-203. doi: 10.1016/j.alit.2020.01.001. Epub 2020 Jan 21.
  • PMID: 28368013
    Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, Vandenberghe I, Pauwels K, Tavernier J, Lambrecht BN, Hammad H, De Winter H, Beyaert R, Lippens G, Savvides SN: Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nat Commun. 2017 Apr 3;8:14937. doi: 10.1038/ncomms14937.

Contoh Produk & Brand

Produk: 9 • International brands: 0
Produk
  • Tezspire
    Injection, solution • 210 mg • Subcutaneous • EU • Approved
  • Tezspire
    Injection, solution • 210 mg/1.9mL • Subcutaneous • US • Approved
  • Tezspire
    Injection, solution • 210 mg • Subcutaneous • EU • Approved
  • Tezspire
    Injection, solution • 210 mg/1.9mL • Subcutaneous • US • Approved
  • Tezspire
    Injection, solution • 210 mg/1.9mL • Subcutaneous • US • Approved
  • Tezspire
    Injection, solution • 210 mg • Subcutaneous • EU • Approved
  • Tezspire
    Solution • 110 mg / mL • Subcutaneous • Canada • Approved
  • Tezspire
    Solution • 110 mg / mL • Subcutaneous • Canada • Approved
Menampilkan 8 dari 9 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul